All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results ConPlas-19, 2020 0.56 [0.20; 1.57]
DAWN-Plasma, 2021 0.61 [0.24; 1.55]
NCT04397757, 2021 0.47 [0.04; 5.45]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
0.82 [0.42 ; 1.61 ] ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021 4 24% 1,072 moderate not evaluable death D28detailed results AlQahtani, 2020 0.47 [0.04; 5.69]
ASCOT, 2021 0.60 [0.06; 5.99]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.12 [0.86; 1.46]
ConPlas-19, 2020 0.49 [0.20; 1.19]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
Horby, 2021 1.01 [0.93; 1.10]
Jamaati, 2021 1.19 [0.38; 3.72]
Kirenga, 2021 1.25 [0.46; 3.39]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Menichetti, 2021 0.75 [0.37; 1.53]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
Rutgers, 2021 0.59 [0.33; 1.06]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shu, 2020 0.38 [0.02; 8.14]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
0.94 [0.89 ; 1.00 ] AlQahtani, 2020, ASCOT, 2021, Co-CLARITY, 2021, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, COPLA-II trial, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Horby, 2021, Jamaati, 2021, Kirenga, 2021, Li, 2020, LIFESAVER, 2021, Menichetti, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, Rutgers, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021 45 10% 52,783 moderate critical deathsdetailed results AlQahtani, 2020 0.47 [0.04; 5.69]
ASCOT, 2021 0.60 [0.06; 5.99]
CAPSID, 2021 0.84 [0.28; 2.50]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59]
CONFIDENT, 2020 0.84 [0.52; 1.37]
ConPlas-19, 2020 0.46 [0.19; 1.15]
COP-COVID-19, 2021 0.96 [0.36; 2.56]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
Fu, 2020 1.00 [0.02; 51.66]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
GRECCO-19, 2020 0.21 [0.02; 1.97]
Holm K, 2021 0.49 [0.08; 2.89]
Horby, 2021 1.01 [0.93; 1.10]
Jamaati, 2021 1.19 [0.38; 3.72]
Kirenga, 2021 1.25 [0.46; 3.39]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Menichetti, 2021 0.75 [0.37; 1.53]
NCT04385199, 2021 0.75 [0.15; 3.77]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Rasheed, 2020 0.13 [0.01; 1.09]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2021 0.85 [0.76; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Rutgers, 2021 0.62 [0.36; 1.07]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shu, 2020 0.38 [0.02; 8.14]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.91 [0.87 ; 0.95 ] AlQahtani, 2020, ASCOT, 2021, CAPSID, 2021, Co-CLARITY, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, COP-COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, DEXA-COVID19, 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Fu, 2020, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, Holm K, 2021, Horby, 2021, Jamaati, 2021, Kirenga, 2021, Li, 2020, LIFESAVER, 2021, Menichetti, 2021, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RCT-TCZ-COVID-19, 2021, RECOVER, 2021, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, Rutgers, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Soin AS (COVINTOC), 2021, Steroids-SARI, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021 68 11% 67,936 moderate critical deaths (time to event analysis only)detailed results COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Rutgers, 2021 0.62 [0.36; 1.07]
Talaschian, 2021 1.25 [0.30; 5.14]
0.89 [0.73 ; 1.09 ] COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, Rutgers, 2021, Talaschian, 2021 7 17% 3,546 moderate not evaluable clinical deteriorationdetailed results CAPSID, 2021 0.63 [0.29; 1.40]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
ConPlas-19, 2020 1.00 [0.65; 1.53]
CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
GRECCO-19, 2020 0.11 [0.01; 1.08]
Kirenga, 2021 0.91 [0.38; 2.17]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
Shu, 2020 0.27 [0.01; 5.58]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
0.78 [0.63 ; 0.97 ] CAPSID, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, ConPlas-19, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, GRECCO-19, 2020, Kirenga, 2021, RCT-TCZ-COVID-19, 2021, Shu, 2020, Soin AS (COVINTOC), 2021 11 0% 1,380 moderate critical clinical improvementdetailed results CAPSID, 2021 1.58 [0.71; 3.49]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Dongsheng Wang, 2020 2.37 [0.40; 13.96]
Li, 2020 1.40 [0.79; 2.49]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
1.45 [1.05 ; 2.00 ] CAPSID, 2021, ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Dongsheng Wang, 2020, Li, 2020, Pouladzadeh, 2021, REMAP-CAP (tocilizumab), 2021, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020 10 63% 1,652 moderate low clinical improvement (14-day)detailed results Li, 2020 2.27 [0.90; 5.72]
Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
2.55 [0.81 ; 8.02 ] Li, 2020, Pandit, 2021, Shashi Bhushan, 2021, Shu, 2020 4 58% 425 moderate not evaluable clinical improvement (28-day)detailed results Li, 2020 1.42 [0.65; 3.10]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
1.66 [0.75 ; 3.67 ] Li, 2020, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020 4 64% 364 moderate not evaluable clinical improvement (7-day)detailed results Li, 2020 0.98 [0.27; 3.58]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
Shu, 2020 6.72 [1.50; 30.07]
2.11 [0.90 ; 4.94 ] Li, 2020, Shashi Bhushan, 2021, Shu, 2020 3 46% 366 moderate not evaluable clinical improvement (time to event analysis only)detailed results ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Li, 2020 1.40 [0.79; 2.49]
Rahmani, 2020 3.41 [1.33; 8.73]
1.56 [1.02 ; 2.39 ] ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Li, 2020, Rahmani, 2020 5 49% 330 moderate serious death or ventilationdetailed results COLCOVID, 2021 0.83 [0.67; 1.02]
CONCOR-1, 2021 1.16 [0.94; 1.43]
ConPlas-19, 2020 0.94 [0.86; 1.02]
CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
DAWN-Plasma, 2021 1.01 [0.64; 1.59]
Menichetti, 2021 0.88 [0.59; 1.32]
RECOVERY, 2021 0.85 [0.78; 0.93]
RECOVERY, 2022 0.90 [0.81; 0.99]
RECOVERY (colchicine), 2021 1.02 [0.96; 1.09]
RECOVERY (plasma), 2021 0.99 [0.93; 1.05]
RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
Rutgers, 2021 0.65 [0.43; 0.99]
Veiga, 2021 1.54 [0.65; 3.63]
0.93 [0.88 ; 0.98 ] COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, DAWN-Plasma, 2021, Menichetti, 2021, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, Veiga, 2021 15 56% 45,990 moderate low hospital dischargedetailed results ConPlas-19, 2020 1.02 [0.82; 1.28]
DAWN-Plasma, 2021 1.06 [0.87; 1.30]
Rahmani, 2020 3.44 [0.64; 18.49]
RECOVERY (colchicine), 2021 0.98 [0.94; 1.03]
RECOVERY (plasma), 2021 0.99 [0.92; 1.07]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
1.06 [0.98 ; 1.14 ] ConPlas-19, 2020, DAWN-Plasma, 2021, Rahmani, 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020 7 71% 33,375 moderate not evaluable mechanical ventilationdetailed results AlQahtani, 2020 0.67 [0.22; 2.02]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COPLA-II trial, 2020 0.58 [0.37; 0.92]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06]
GRECCO-19, 2020 0.17 [0.02; 1.48]
Holm K, 2021 0.39 [0.01; 12.68]
Jamaati, 2021 1.38 [0.45; 4.20]
NCT04397757, 2021 0.41 [0.13; 1.35]
Rahmani, 2020 0.29 [0.05; 1.56]
RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
RECOVERY, 2022 0.87 [0.74; 1.02]
RECOVERY (colchicine), 2021 1.04 [0.93; 1.16]
RECOVERY (plasma), 2021 0.98 [0.88; 1.09]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
Rutgers, 2021 0.65 [0.35; 1.24]
Sakoulas, 2020 0.19 [0.03; 1.11]
Shu, 2020 0.59 [0.02; 14.04]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
Tabarsi, 2020 1.49 [0.59; 3.78]
0.89 [0.80 ; 0.98 ] AlQahtani, 2020, COL-COVID (Pascual-Figal), 2021, COPLA-II trial, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, Holm K, 2021, Jamaati, 2021, NCT04397757, 2021, Rahmani, 2020, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, Sakoulas, 2020, Shu, 2020, Soin AS (COVINTOC), 2021, Tabarsi, 2020 21 25% 37,123 moderate critical mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
DAWN-Plasma, 2021 1.08 [0.65; 1.80]
0.97 [0.62 ; 1.52 ] CP-COVID-19, 2021, DAWN-Plasma, 2021 2 0% 583 moderate not evaluable radiologic improvement (14-day)detailed results Jamaati, 2021 4.89 [1.15; 20.79]
Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
Tabarsi, 2020 2.33 [0.45; 12.00]
3.02 [1.77 ; 5.14 ] Jamaati, 2021, Rashad (CLARI vs SoC), 2021, Tabarsi, 2020 3 0% 332 moderate not evaluable viral clearance detailed results CP-COVID-19, 2021 1.12 [0.16; 7.84]
Pandit, 2021 2.33 [0.55; 9.83]
Raman, 2021 36.42 [10.85; 122.18]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
3.87 [1.04 ; 14.37 ] CP-COVID-19, 2021, Pandit, 2021, Raman, 2021, Salman, 2020, Shashi Bhushan, 2021 5 76% 511 moderate not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Kirenga, 2021 0.95 [0.76; 1.19]
Pandit, 2021 10.23 [1.12; 93.35]
Raman, 2021 36.42 [10.85; 122.18]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
1.08 [0.07 ; 16.52 ] CP-COVID-19, 2021, Kirenga, 2021, Pandit, 2021, Raman, 2021, Shashi Bhushan, 2021 5 97% 1,684 moderate not evaluable viral clearance by day 7detailed results Kirenga, 2021 0.87 [0.65; 1.16]
Pandit, 2021 2.33 [0.55; 9.83]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.59 [0.67 ; 3.76 ] Kirenga, 2021, Pandit, 2021, Salman, 2020, Shashi Bhushan, 2021 4 73% 439 moderate not evaluable ICU admissiondetailed results COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75]
Rahmani, 2020 0.37 [0.14; 1.00]
Rutgers, 2021 0.96 [0.55; 1.68]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
Tabarsi, 2020 0.56 [0.18; 1.74]
0.86 [0.65 ; 1.14 ] COL-COVID (Pascual-Figal), 2021, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Rahmani, 2020, Rutgers, 2021, Soin AS (COVINTOC), 2021, Tabarsi, 2020 9 0% 1,193 moderate serious recoverydetailed results Talaschian, 2021 0.64 [0.14; 2.92]
0.64 [0.14 ; 2.92 ] Talaschian, 2021 1 0% 36 NA not evaluable serious adverse eventsdetailed results CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CONCOR-1, 2021 1.27 [1.02; 1.58]
ConPlas-19, 2020 0.89 [0.43; 1.86]
Dongsheng Wang, 2020 0.91 [0.02; 47.31]
Pandit, 2021 0.95 [0.02; 50.33]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.22 [1.05 ; 1.41 ] CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, CONCOR-1, 2021, ConPlas-19, 2020, Dongsheng Wang, 2020, Pandit, 2021, Raman, 2021, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021 12 0% 4,363 moderate low superinfectiondetailed results Rahmani, 2020 0.18 [0.02; 1.59]
0.18 [0.02 ; 1.59 ] Rahmani, 2020 1 0% 66 NA not evaluable adverse eventsdetailed results COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
Dongsheng Wang, 2020 9.64 [2.76; 33.75]
Kirenga, 2021 1.13 [0.50; 2.58]
Pandit, 2021 1.68 [0.47; 5.97]
Raman, 2021 1.36 [0.56; 3.30]
Sakoulas, 2020 1.00 [0.02; 53.46]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shu, 2020 2.48 [0.05; 132.54]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
Veiga, 2021 1.65 [0.81; 3.37]
1.50 [1.09 ; 2.06 ] COL-COVID (Pascual-Figal), 2021, Dongsheng Wang, 2020, Kirenga, 2021, Pandit, 2021, Raman, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shu, 2020, Soin AS (COVINTOC), 2021, Veiga, 2021 10 33% 987 moderate critical 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-26 06:36 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290